Recent Event Highlights: Vivus Weight-Loss Pill Qnexa Wins Backing of FDA Panel - BusinessWeek, US to Review Diet Treatment Once Rejected, Reuters Health News Summary - Chicago Tribune, Study: Colonoscopies prevent deaths - The Seattle Times, HP shares fall, Vivus skyrockets in after hours - MarketWatch, US HOT STOCKS: Vivus, Orexigen, Arena Active In Late Trading - Wall Street Journal, and 123 more...
Created by dipity on Dec 16, 2008
Last updated: 02/23/12 at 12:03 AM
Los Angeles TimesVivus Weight-Loss Pill Qnexa Wins Backing of FDA PanelBusinessWeek22 (Bloomberg) -- Vivus Inc.'s weight-loss pill Qnexa won the backing of a US advisory panel as the company seeks to gain approval for the first new obesity drug in 13 years. The shares doubled in late trading. Advisers to the Food and Drug ...If Qnexa gets the green light, who would get the drug?Los Angeles TimesQnexa: FDA Panel Recommends Approval for Weight-Loss DrugTIMEFDA Panel Votes in Favor of QnexaMedPage TodayBloomberg -Huffington Postall 408 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFdIq8IHJYtN7130RqMsFyhDiA4EQ&url=http://news.businessweek.com/article.asp?documentKey%3D1376-LZTCPW1A1I4H01-4K0N68IBOPCB09O0LAH45B1QIO
Click to video-stream-blog.info to Watch full video " US to Review Diet Treatment Once Rejected " for FREE!!!
Reuters Health News SummaryChicago TribuneUS advisers back experimental obesity pill SILVER SPRING, Maryland (Reuters) - Experimental obesity drug Qnexa won the backing of US health advisors on Wednesday, raising hopes for approval of the first prescription weight-loss pill in 13 years.and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNF7_4R6Fc1vDwKqru5BfDhBpGWI6g&url=http://www.chicagotribune.com/sns-rt-healthn22121256-20120222,0,7338412.story
PLEASE SUBSCRIBE Please visit: www.ggnonline.com or http for the latest news commentary by Global Government News Please donate to GGN: www.paypal.com because it would be greatly appreciated. Thank you. HEADLINES WITH LINKS: POLICE STATE - Cop Gets Away With Tasing A Handcuffed Girl And Leaving Her Braindead bit.ly Relatives of Honduras Prison Fire Storm Morgue bit.ly Chinese Police Warn Pro-Democracy Activist for Website bit.ly New FDA analysis finds lead in all 400 lipstick products tested bit.ly EPA Updates Science Assessment for Dioxins / Air emissions of dioxins have decreased by 90 percent since the 1980s 1.usa.gov Millions of Pounds of Toxic Poison to Flood US Farmland bit.ly Monsanto's Bt GMO corn to be sold at Wal-Mart with no indication it is genetically modified bit.ly South American illness baffles scientists as workers succumb to kidney failure at rates unseen anywhere bit.ly Settlement Talks Pick Up Ahead of BP Oil Spill Trial nyti.ms 260 Dead Dolphins Scattered on Shoreline of Peru, Just Days After Mysterious US Incident bit.ly Radiation detected 400 miles off Japanese coast yhoo.it Scientists debate mutant bird flu risk at WHO yhoo.it Incurable Virus Killing Thousands Of Lambs bit.ly Artificial hamburger meat successfully grown in vat of bovine fetal cells; You want some fries with that? bit.ly Pot-Smoking Drivers Safer Than Drinkers Behind Wheel, Teens Say buswk.co Study Shows Marijuana-Impaired Drivers Twice as Likely To Crash bit.ly Schumer, Gillibrand ...
Study: Colonoscopies prevent deathsThe Seattle TimesLOS ANGELES — A panel of medical experts voted overwhelmingly Wednesday to endorse the controversial weight-loss drug Qnexa, clearing the way for the Food and Drug Administration (FDA) to approve a new prescription obesity medication for the first ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHcWjqJz9tCTA-DK0TVbuLjeZQQ_g&url=http://seattletimes.nwsource.com/html/nationworld/2017572498_medical23.html
HP shares fall, Vivus skyrockets in after hoursMarketWatchbased biopharmaceutical company said a US Food and Drug Administration advisory panel recommended in a 20-to-2 vote that the agency approve its weight-loss treatment Qnexa. The shares came off the trading halt and surged 97% to $20.83 in heavy volume.and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEu7IGy-cs1ZhSFtbXssTAaK4PKQw&url=http://www.marketwatch.com/story/h-p-analog-devices-reports-due-after-hours-2012-02-22?link%3DMW_latest_news
US HOT STOCKS: Vivus, Orexigen, Arena Active In Late TradingWall Street JournalAmong the companies whose shares are actively trading after hours are Vivus Inc.'s (VVUS), Orexigen Therapeutics (OREX) and Arena Pharmaceuticals Inc. (ARNA) A federal advisory panel on Wednesday overwhelmingly backed Vivus's weight-loss drug Qnexa, ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNE5zhvss0WsHyX2JeSe8GYHs6bluQ&url=http://online.wsj.com/article/BT-CO-20120222-721011.html
FDA advisory panel votes in favor of approving obesity drug QnexaBoston.comBy Deborah Kotz, Globe Staff SILVER SPRING, Md. -- A US Food and Drug Administration advisory committee voted overwhelmingly this afternoon in favor of approving the anti-obesity drug Qnexa. It would be the first new prescription weight-loss drug in 13 ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFzXSXXc6qPSjdPtuwKVoNiO29MVQ&url=http://www.boston.com/Boston/dailydose/2012/02/fda-advisory-panel-votes-favor-approving-obesity-drug-qnexa/HBMQJ0qFDK3cXDPt2VrOGI/
FDA panel backs previously rejected obesity pillSanta Rosa Press DemocratBy MATTHEW PERRONE AP Health Writer SILVER SPRING, Md. - A panel of advisers to the Food and Drug Administration overwhelmingly backed approval for a highly anticipated anti-obesity pill called Qnexa, a drug which the FDA previously rejected due to ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHMSlu75Bsz0jEs9ZFei8C5FgMbpg&url=http://www.pressdemocrat.com/article/20120222/APF/1202220961
Climate Scientist Admits To Lying, Leaking DocumentsNorth Country Public RadioIn a reversal, a panel of experts is advising the Food and Drug Administration to approve Qnexa, a weight-loss pill, that was rejected in 2010. The potential benefits for overweight people exceed the risks, such as birth defects and increased heart ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGZeu90VlOvSe5B_FmtVjrrrgQedw&url=http://www.northcountrypublicradio.org/news/npr/147263862/climate-scientist-admits-to-lying-leaking-documents
FDA panel overwhelmingly backs previously rejected anti-obesity pill QnexaWDBJ7The FDA panel of outside physicians voted 20-2 in favor of the weight loss drug Qnexa, setting the stage for a potential comeback for a drug that has been plagued by side effects since it was first submitted to the agency in 2010.
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHg4EuIHU8wWuob4Afp3E8aqrdFvg&url=http://www.wdbj7.com/news/sns-bc-us--dietpill-fdameeting,0,5153424.story
Excerpt
...hydrochloride has been used as an appetite suppressant since 1959 — typically in does of 15 milligrams to 37.5 milligrams. The Qnexa formula — which comes in three doses — contains 3.75 to 15 milligrams of phentermine. Topiramate is approved for treatment...
Source Info
Mother Nature Network
Related Topics
http://www.mnn.com/green-tech/research-innovations/stories/qnexa-a-magic-diet-pill
Excerpt
...is the appetite suppressant phentermine, the safer "phen" part of the infamously unsafe fen-phen diet drug. The other half of Qnexa is the seizure/migraine drug topiramate. The topiramate label lists some scary side effects: eye problems, decreased sweating...
Source Info
CBS News
http://feeds.cbsnews.com/~r/CBSNewsGamecore/~3/0mYVhMvzM7U/
Excerpt
...group. The FDA standard is that 35% of people must lose 5% of body weight. In a follow-up study, people continuing to take Qnexa for a second year regained some of the weight they lost the first year. They did not regain as much weight as people taking a placebo....
Source Info
WebMD
Related Topics
http://www.webmd.com/diet/news/20120217/panel-to-ponder-fate-of-qnexa-weight-loss-pill?src=RSS_PUBLIC
TIMEUS to Review Diet Treatment Once RejectedNew York TimesThe FDA rejected the drug under review, Qnexa, in 2010, amid safety concerns, and the drug's manufacturer is now presenting additional data to argue its case. But thousands of people here in central California, where Qnexa's inventor ran a weight-loss ...Diet Drug Qnexa: FDA to Reconsider Safety ConcernsTIMEVivus Obesity Pill May Need More Heart Data Before ApprovalBusinessWeekModest hope for FDA approval of Vivus obesity drugChicago TribuneWall Street Journal -Reutersall 268 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEztevO34rMxHM2IFdkojikts2emA&url=http://www.nytimes.com/2012/02/17/business/diet-treatment-already-in-use-to-get-fda-review.html
Meet the Beatles! My bands music: resingypsy.bandcamp.com Drummers channel youtube.com 1. ash wednesday 2. qnexa 3. argentina train crash 4. enquirer 5. kate walsh 6. national enquirer 7. lent 8. republican debate 9. star jones 10. bridge to nowhere 11. gop debate 12. marie colvin 13. kombucha tea 14. lint 15. nfl combine 16. danica patrick 17. cm punk 18. wheres my refund 19. pga tour 20. lewis black adele youtu.be
This kid knows how to speak Eagle.
Please listen to my band! resingypsy.bandcamp.com I really dig this solo, its not spot on.. I figured it out off the record and put my own spin on it. If you like what you hear subscribe for more! Thanks 1. ash wednesday 2. qnexa 3. argentina train crash 4. enquirer 5. kate walsh 6. national enquirer 7. lent 8. republican debate 9. star jones 10. bridge to nowhere 11. gop debate 12. marie colvin 13. kombucha tea 14. lint 15. nfl combine 16. danica patrick 17. cm punk 18. wheres my refund 19. pga tour 20. lewis black adele youtu.be "Led Zeppelin" "Whole Lotta Love" "guitar" "guitar_solo" "Jimmy_page" "rock and roll" "music" "blues" "rock" "metal" "Rock Music"
NOSTALGIA I CHOOSE YOU! Pokemon Trainer Battle theme done on guitar Gibson Les Paul DI to logic express 8 on an iMac 1. ash wednesday 2. qnexa 3. argentina train crash 4. enquirer 5. kate walsh 6. national enquirer 7. lent 8. republican debate 9. star jones 10. bridge to nowhere 11. gop debate 12. marie colvin 13. kombucha tea 14. lint 15. nfl combine 16. danica patrick 17. cm punk 18. wheres my refund 19. pga tour 20. lewis black adele www.youtube.com
Contest closed, 2nd place! Please check out my bands resingypsy.bandcamp.com http Im Dre DiMura this is My spin on the lick for the Guitar World Lick of the Day Challenge. You can listen to my original music @ resingypsy.bandcamp.com Thanks for the support, remember if you dig to please LIKE the video, as the video with the most LIKES wins. 1. ash wednesday 2. qnexa 3. argentina train crash 4. enquirer 5. kate walsh 6. national enquirer 7. lent 8. republican debate 9. star jones 10. bridge to nowhere 11. gop debate 12. marie colvin 13. kombucha tea 14. lint 15. nfl combine 16. danica patrick 17. cm punk 18. wheres my refund 19. pga tour 20. lewis black adele www.youtube.com
i've been searching this moment for so long but qnexa(1 of the guardians) found it. lol Sooyoung rubs the back of Siwon after they hugging each other. oh gosh, they're so freaking cute together. best couple ever -this is my 4th time to upload this video. lol idk what happened. oh well just enjoy this moment and be happy,lol
Our options team has been watching VIVUS (NASDAQ:VVUS) call options which are currentlytrading around 18 times their average volume, on news that the company will resubmit its drug QNEXA for FDA approval. Carnival Corporation (NYSE:CCL) calls are also very active at around 14 times their average amount ahead of their quarterly earnings report next week. Also lighting up the screens of options traders are Toll Brothers (NYSE:TOL) calls, trading at 13.3 times their average volume. Energy XXI (NASDAQ:EXXI) is seeing its call options trade at 10.8 times their average amount after several investors placed bullish bets on the company. Finally, Infinera (NASDAQ:INFN) calls close out the list at 8.8 times their average volume after the company announced a new product. VIVUS, Inc. develops and manufactures therapies for the treatment of men with erectile dysfunction. The Company is currently marketing MUSE and ACTIS in the United States and has license agreements with other companies to market its products internationally. VIVUS is also conducting clinical trials for another treatment. Vivus (NASDAQ:VVUS) has a potential upside of 15.4% based on a current price of $8.79 and an average consensus analyst price target of $10.14.
based on this video..soowon is real.the way they hug and holding hands are just heartbreakingly beautiful.(i'm jealous again.keke)this moment is really..really..daebak...i just can't get over.. After hugging each other, you can see Sooyoung's hand still at the back of Siwon. Then Siwon sees her hand, holds it and slightly pulled her until they stopped when people gathered around them - qnexa They really know what's the real score between this couple. their reaction is..hhhmmm...something's fishy...kekeke No matter what Siwon and Sooyoung say about their status, we still believe that there's something about them.. sometimes... actions speak louder than words. Uploaded by: ITALIANgirl Researched by: qnexa
Are you ready for the sweetest and the most romantic hug of all time? well get prepared.,.keke.. the best peak of this video is, when sooyoung hold the head of siwon while they hugging each other. OMG! i'm so jealous.. one more thing for this video : Sooyoung is always the (first) one to be hugged by Siwon unlike others. (qnexa). keke especial thanks to qnexa for giving this link :) SOOWON fighting!!! Uploaded by: ITALIANgirl i wish the format for this video is ok.
dietspotlight.com begins its review of QNexa by noting that when it comes to weight loss products and dieting pills, many of these products come under very close scrutiny from the FDA. The main reason for this is because of the potential for these products to have serious health consequences on the body of the user. QNexa is one such product, with the results of its study causing it to be banned for purchase by the FDA.
NZ crew hopskotch chowing their worlds routine before heading over to the world hip hop champs in Las Vegas.
Blues for Alice jam Please check out my bands resingypsy.bandcamp.com http 1. ash wednesday 2. qnexa 3. argentina train crash 4. enquirer 5. kate walsh 6. national enquirer 7. lent 8. republican debate 9. star jones 10. bridge to nowhere 11. gop debate 12. marie colvin 13. kombucha tea 14. lint 15. nfl combine 16. danica patrick 17. cm punk 18. wheres my refund 19. pga tour 20. lewis black adele Charlie_Parker Blues Blues_for_Alice Guitar Solo Jazz Music www.youtube.com
Vivus (NASDAQ:VVUS) said its effort to win regulatory approval for its weight-loss pill Qnexa may be helped by a study showing little risk of birth defects in children of women who took one of the medicine's ingredients, according to a Bloomberg report. Vivus has a potential upside of 16.6% based on a current price of $8.21 and an average consensus analyst price target of $9.57.
Welcome to the Financial News Network Options Report. On the call side, Vivus calls are at 10 times the average amount after positive news was released about its experimental diet pill Qnexa. Westport Innovations calls are at over 7 times the average volume as investors are bullish on the sector today. Gannett calls are not far behind at just over 7 times their normal volume. Bank of Ireland calls are trading at close to 5 times the normal amount after news that the Irish government will refinance their banking system. Finally, Avalon Rare Metals closes out the list with 4.7 times their average amount of calls. Shares of the company are trading close to their 52 week high today as well. Taking a look at the put side of the ledger, Boston Scientific puts are very active today at close to 15 times the average volume after several investors bet bearishly on the company. Duoyuan Global Water puts are at 11 times their normal volume after the company was downgraded by analysts. CA, Inc puts are also very active today at 5.5 times the average amount today. Juniper Networks puts are at just over 4 times the normal amount today as several investors are betting that the company will continue on its downward slide. Finally, MBIA closes out the list with 4 times the average amount of puts. This has been you daily options update from the Financial News Network. Stay tuned for more insight into where the big money is placing their bets each day.
Vivus Inc's (NASDAQ:VVUS) share price jumped after research showed its experimental diet pill Qnexa also helped lower blood pressure and cholesterol. Qnexa, taken once a day, helped reduce dependence on blood-pressure pills by as much at 19%, and decrease triglycerides by 26%, according to research presented yesterday. No new safety risks were discovered among the 675 overweight and obese patients that participated in the study. The FDA rejected Vivus' application for Qnexa last October, raising concerns the drug may cause heart risks and birth defects. Regulators have stated they want to see additional benefits of diet pills outside of weight loss to support an approval for a subgroup of patients, rather than for all overweight Americans. Vivus has a potential upside of 47.1% based on a current price of $7.17 and an average consensus analyst price target of $10.56.
Vivus (VVUS) is up by double digits in early trading, after it says long-term data demonstrated patients treated with the investigational drug QNEXA for two years showed reductions in blood pressure and the use of antihypertensive medications as well as improvements in lipid levels following significant reductions in weight loss as compared to those in the placebo group over two years.
The Food and Drug Administration issued a health advisory for one of the compounds in Vivus Inc's (NASDAQ:VVUS) diet drug Qnexa. The FDA warned that pregnant women who consume the drug topiramate are at a higher risk of giving birth to a child with a cleft lip or cleft palate, and advised doctors to warn women of childbearing age of the risk when prescribing the medication. The regulator recently declined to approve Qnexa in part because of concerns over the prenatal risks of the medication, which is a combination of the drugs topiramate and phentermine. Topiramate, developed by Johnson & Johnson (NYSE:JNJ) and marketed under the brand name Topamax, has been on the market for years to treat epilepsy and migraine headaches, and is available generically in the US Vivus is gathering additional information about the prenatal risks associated with the drug and plans to resubmit its market application by the end of the year. Vivus is trading down 10.5% at $6.31 per share.
Richie Blackmore's solo from Burn. Check out my bands music @ resingypsy.bandcamp.com facebook.com 1. ash wednesday 2. qnexa 3. argentina train crash 4. enquirer 5. kate walsh 6. national enquirer 7. lent 8. republican debate 9. star jones 10. bridge to nowhere 11. gop debate 12. marie colvin 13. kombucha tea 14. lint 15. nfl combine 16. danica patrick 17. cm punk 18. wheres my refund 19. pga tour 20. lewis black adele www.youtube.com Deep_Purple, Richie_Blackmore, Metal, Burn, guitar_solo, guitar, music, rock, blues, Highway_star, Smoke_on_the_wate
Do this instead: www.tscHeartofaChampionProgram.com Be aFit Fast and Strong All-Natural Athlete. Chris Krueger's health and fitness channel, TSC, Transformation Super Challenge. Today we look at some exciting exercise that you should never do. At best they're totally pointless at worst, their dangerous. I strongly encourage everyone to go outside and play. Run, jump, and have fun. Life is to short to spend it inside watching reality tv and eating microwave pizza rolls. Challenge yourself with new activities and push yourself to be your best. And watch my vlog, Transformation Truth If you set goals to be fitter, faster, and stronger and pursue them with the Heart of a Champion, everything else will naturally fall into place (like getting ripped abs and buff arms). Be your best. Best, CK PS Music by Galaxy Farm get their EP on iTunes. There are TSCers all over the world transforming their lives right now. TSCers are making it happen in Hong Kong, Germany, France, Italy Spain, Russia, Finland, Sweden, Norway, The Netherlands, Austria, Australia, Brazil, South Africa, Switzerland, Andorra and everywhere in between. You can make it happen too. Challenge yourself with the TSC Heart of a Champion Program and see how much you can accomplish in the next 70 days. We're in Europe, Asia, Africa, North, and South America. Make it happen. www.tscHeartofaChampionProgram... http twitter.com transformationsuperchallenge.b... TSC Heart of a Champion Torrent Official http
www.tscHeartofaChampionProgram.com ... Be aFit Fast and Strong All-Natural Athlete. Episode 19 of Chris Krueger's Transformation Truth. The Health and Fitness vlog that separates fact from fiction and gives you the truth. It's all abut how to achieve true & health and fitness and dispelling the ridiculous myths and bogus supplements that the "health and fitness" industry spend millions of dollars try to brainwash us with. Honest, up front and shooting from the hip. Chris Krueger injects reality into a world gone mad. This Transformation Truth focuses on low-carb diets like the atkins diet. Chris Krueger discusses how we can avoid this failing on this diets that don't work. Low-carb diets burn muscle and cause increased bodyfat. Begin the journey to true health and fitness and unlimited success. Chris Krueger's 70 day body transformation. Following a devastating back injury with two herniated discs in my lower back, I gained over 40 pounds because of poor eating and inactivity. The best on youtube. Get the Heart of a Champion and make it happen for yourself. It's important for all of us to reach and strive for our true potential. We should be fit, fast, and strong, natural athletes. We should look, feel and be our best. Part of that is using proper form so that we can safely train our bodies and get results as quickly as possible. I strongly encourage everyone to go outside and play. Run, jump, and have fun. Life is to short to spend it inside watching reality tv and ...
www.tscHeartofaChampionProgram.com ... Be aFit Fast and Strong All-Natural Athlete. Episode 18 of Chris Krueger's Transformation Truth. The Health and Fitness vlog that separates fact from fiction and gives you the truth. It's all abut how to achieve true & health and fitness and dispelling the ridiculous myths and bogus supplements that the "health and fitness" industry spend millions of dollars try to brainwash us with. Honest, up front and shooting from the hip. Chris Krueger injects reality into a world gone mad. Transformation Truth focuses on obesity and diabetes. Chris Krueger discusses how we can avoid this terrible disease that results in limb amputation, kidney failure, blindness. Begin the journey to true health and fitness and unlimited success. Chris Krueger's 70 day body transformation. Following a devastating back injury with two herniated discs in my lower back, I gained over 40 pounds because of poor eating and inactivity. The best on youtube. Get the Heart of a Champion and make it happen for yourself. It's important for all of us to reach and strive for our true potential. We should be fit, fast, and strong, natural athletes. We should look, feel and be our best. Part of that is using proper form so that we can safely train our bodies and get results as quickly as possible. I strongly encourage everyone to go outside and play. Run, jump, and have fun. Life is to short to spend it inside watching reality tv and eating microwave pizza rolls. Challenge ...
"The FDA rejected Vivus' (NASDAQ:VVUS) obesity drug Qnexa, however, shares of Vivus are trading 21.7% higher in premarket action as investors seem to be backing the company's confidence in the ""efficacy and safety"" of the drug. Vivus said it will have the research the FDA requested ready for submission in approximately six weeks. Vivus said in its press release, ""As part of the written response, VIVUS plans to compile analyses integrating existing nonclinical and clinical data to provide a comprehensive assessment of the teratogenic potential of topiramate. In addition, VIVUS plans to provide several new analyses to demonstrate QNEXA does not increase the risk for major cardiovascular events, which would include data from our studies."""
"Good Morning. It's Friday, October 29, 2010. At this hour, US equity futures are down. Overseas, the Asian markets declined, while the European markets are lower. VIVUS (VVUS) announced that it received a Complete Response Letter from the FDA regarding its New Drug Application for the investigational new drug QNEXA. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form...Donaldson (DCI) combines its hydraulic filtration businesses under one umbrella to accelerate growth in its liquid filtration product lines...Pfizer (PFE) announced that the Japanese Ministry of Health, Labour and Welfare approved Lyrica, or pregabalin, capsules for the treatment of peripheral neuropathic pain...General Growth Properties (GGP) named Sandeep Mathrani as CEO. "
Coming Catalysts for Biotech Stocks During OctoberMinyanville.comThe FDA will make its decision on Vivus' Qnexa. An advisory panel to the FDA voted against approval in July. The panel thought that risks surrounding ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHvalVt0I0KZ8aAVk9-hIfnOgxadw&url=http://www.minyanville.com/businessmarkets/articles/lorcaserin-qnexa-linjeta-embeda-oxycontin-diabetes/9/30/2010/id/30332
Tapping into a dietary 'marvel'OregonLive.comNone of the names is familiar -- Lorcaserin, Qnexa and Contrave -- or terribly catchy. And recent history is littered with weight-loss drugs that proved ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGIig8WPVnKKzJpOGD46ATQtdvVzQ&url=http://www.oregonlive.com/opinion/index.ssf/2010/09/tapping_into_a_dietary_marvel.html
Vivus' Qnexa Panel: What Might Have BeenSeeking AlphaA lot of talk about what impact this data may have had on Qnexa's advisory panel meeting has taken place – and with good reason. ...Will the FDA Give Vivus More Time Before the Final Judgment on Qnexa?Seeking AlphaVivus Races to Capture U.S. Approval of Obesity DrugSeeking Alphaall 3 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEbhSz8st-Ttr-fMBVRLOidg2zeUg&url=http://seekingalpha.com/article/227033-vivus-qnexa-panel-what-might-have-been
Positive Data on Vivus' QnexaZacks.comVivus Inc. (VVUS - Snapshot Report) recently announced positive data from a two-year trial of its weight loss, once-daily pill Qnexa. ...Biotech Stock Mailbag: VivusTheStreet.comWeighty Issues With Vivus Take a Turn for the BetterSeeking AlphaFDA Decision On Avandia Is A Positive For VIVUS (VVUS) and Orexigen (OREX ...StreetInsider.com (subscription)all 8 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFP4D6SQPXR1lhSuHEhs50eFTrMbg&url=http://www.zacks.com/stock/news/40562/Positive%2BData%2Bon%2BVivus%2592%2BQnexa
Is There Still Hope for the Weight Loss Drug Qnexa?TIMEBack in July, an FDA advisory panel voted not to recommend obesity drug Qnexa for government ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFBjAnvypx8gQTypKEXfaJ9QSYriQ&url=http://healthland.time.com/2010/09/21/is-there-still-hope-for-the-weight-loss-drug-qnexa/
ConAgra, Buckle, NYT, Vivus among big moversThe Associated PressNASDAQ Vivus Inc., up 56 cents at $6.74 The drug maker said results from a two-year study of its obesity drug Qnexa showed the drug's safety. ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFK2B-NdM_J-3y8dtysR6iuvmmN1Q&url=http://www.google.com/hostednews/ap/article/ALeqM5g4tAp3j2HuG3m_dAja9GlZb_BUzgD9ICHF201
Health JackalAhead of the Bell: Vivus rises on Qnexa study dataBusinessWeekShares of Vivus Inc. rose almost 12 percent in pre-market trading Tuesday after the company reported results from a two-year study of its obesity drug Qnexa ...Vivus Reports Positive Data on Diet DrugWall Street JournalVivus: Weight Loss Extends Two YearsTheStreet.comVivus climbs while drug-stock indexes hold flat lineMarketWatchBeacon Equity Research -Wall Street Pit -Health Jackalall 78 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFcBpH-1Jev6H4bfmIWio_ju1fVWQ&url=http://www.businessweek.com/ap/financialnews/D9ICAJTG0.htm
Shares of Vivus (NASDAQ:VVUS) are trading over 10% higher Tuesday premarket after the company that develops and manufactures treatments for erectile dysfunction reported positive top-line results from a two-year study of its QNEXA controlled release capsules, which is an investigational therapy for the treatment of obesity. The findings come from the SEQUEL study, a 108 weeks study including 675 obese patients. Patients who took the top dose of QNEXA were able to get and maintain average weight loss through two years of 11.4% of their initial body weight, or 26 pounds. The most common side effects seen were constipation, tingling, dry mouth, altered taste and insomnia. SmarTrend currently has Vivus in a Downtrend and is currently monitoring these developments and will alert subscribers to any change of trend.
Scientific American (blog)FDA To Obesity Drugs: Drop DeadInvestopediaThis ruling is not altogether shocking in the wake of Vivus' (Nasdaq: VVUS) similar rejection on Qnexa, but it should certainly have Orexigen (Nasdaq:OREX) ...Orexigen last contender in lucrative diet marketHa'aretzNew anti-obesity drug dismissed by FDA panelScientific American (blog)Orexigen Plans Long-term Study Of Diet Drug After ApprovalCapital.gr (press release)Pharmaceuticals & Healthcare Insight (registration)all 23 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNH6cf04v9YLSL5goZF6EVMphDJF3g&url=http://stocks.investopedia.com/stock-analysis/2010/FDA-To-Obesity-Drugs-Drop-Dead-ARNA-VVUS-OREX-PFE0920.aspx
VIVUS Inc. is Today's Focus Stock on MicroStockProfit.comMarketWatch (press release)One of these investigational products, Qnexa, is in phase III clinical trials for obesity and in phase II clinical trials for diabetes. ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGxr1PAKqcD8yld7kRi61UVjfHndw&url=http://www.marketwatch.com/story/vivus-inc-is-todays-focus-stock-on-microstockprofitcom-2010-09-16?reflink%3DMW_news_stmp
Bloomberg briefingSan Francisco ChronicleMountain View's Vivus is competing to create the next generation of weight-loss drugs, though the same panel recommended against approving its Qnexa diet ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEzrxRoSaLACJFPAdMPS7U6hhpjFQ&url=http://www.sfgate.com/cgi-bin/article.cgi?f%3D/c/a/2010/09/13/BUFV1FDCPD.DTL
Long/Short Positions on these 3 Healthcare Stocks Contingent on FDA DecisionsBeacon Equity Research (blog)ARNA's drug is the favorite over VIVUS's (Nasdaq: VVUS) QNEXA and Orexigen's (Nasdaq: OXGN) Contrave, yet many familiar with the study are skepitcal that ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGYzqNTnyJaUi0Eq40pOX300qbWhQ&url=http://www.beaconequity.com/longshort-positions-on-these-3-healthcare-stocks-contingent-on-fda-decisions-2010-09-13/
Update Sources